Is onconova Therapeutics a good investment?

Is onconova Therapeutics a good investment?

Onconova Therapeutics has received a consensus rating of Buy.

Why is onconova Therapeutics stock so low?

Onconova Therapeutics' stock price plummeted by more than 70% Monday morning after the company announced disappointing results from late-stage testing of its lead new drug candidate. ... The disclosure sent Onconova's (NASDAQ: ONTX) stock price down from $1.01 per share to 30 cents in morning trading.

What does onconova therapeutics do?

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation.

Is ONTX going to reverse split?

Onconova Therapeutics, Inc. (ONTX) will effect a one-for-fifteen (1-15) reverse split of its common stock. The reverse stock split will become effective on Friday, . In conjunction with the reverse split, the CUSIP number will change to 68232V801.

Will onconova Therapeutics stock go up?

The Onconova Therapeutics stock price gained 3.26% on the last trading day (Thursday, 23rd Dec 2021), rising from $2.76 to $2.85....Predicted Opening Price for Onconova Therapeutics of Monday, Decem.

Fair opening price Decem	Current price
$2.82	$2.85 (Overvalued)

What will ONTX stock go up to?

Onconova Therapeutics Inc (NASDAQ:ONTX) The 2 analysts offering 12-month price forecasts for Onconova Therapeutics Inc have a median target of 11.50, with a high estimate of 12.00 and a low estimate of 11.00. The median estimate represents a +302.10% increase from the last price of 2.86.

What happened to onconova?

Earlier this week, Onconova Therapeutics released its earnings for the first quarter of 2021 and posted a net loss of $4.7 million compared to a net loss of $5.1 million in the same period in 2020. The company's R&D expense fell from $3.4 million to $1.9 million over the period.

What happened ONTX 2013?

18, 2013) Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the discontinuation of the Phase 3 ONTRAC study of intravenous (IV) rigosertib plus gemcitabine in front-line metastatic pancreatic cancer.

What happened to Onconova Therapeutics?

Earlier this week, Onconova Therapeutics released its earnings for the first quarter of 2021 and posted a net loss of $4.7 million compared to a net loss of $5.1 million in the same period in 2020. The company's R&D expense fell from $3.4 million to $1.9 million over the period.

Is Rigosertib FDA approved?

Rigosertib is an investigational drug, which means that it has not been approved by the U.S. Food and Drug Administration (FDA) to treat any diseases.

What kind of company is Onconova Therapeutics?

• NEWTOWN, Pa., (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with …

What is Onconova doing to Advance Precision Oncology?

• Aug. 12, 2019 – Onconova entered into a Partnership with Mission Bio to advance precision oncology clinical trials employing single-cell genomics. The alliance will leverage Mission Bio’s Tapestri Platform to investigate Onconova’s novel cancer therapy rigosertib, through clinical trials.

How does Onconova Therapeutics' short interest stack up in August?

• Onconova Therapeutics saw a increase in short interest in August. As of August 13th, there was short interest totaling 721,300 shares, an increase of 12.2% from the July 29th total of 642,600 shares. Based on an average trading volume of 653,000 shares, the days-to-cover ratio is currently 1.1 days.

What does the 1-15 reverse split mean for Onconova Therapeutics?

• The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 20th 2021. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split.